2006 Biosimilars Diabetes 
European Pharmaceutical Review
AUGUST 16, 2023
Sandoz has announced positive results from the MYLIGHT Phase III study for its biosimilar aflibercept, for patients living with wet macular degeneration. The confirmatory efficacy and safety study ( NCT04864834 ) demonstrated therapeutic equivalence between the biosimilar aflibercept and the reference biologic, Eylea®.
Drug Channels
JULY 29, 2020
In this issue: Pricing problems for diabetes treatments Controversy over Regeneron’s copay support Massachusetts concedes that coupons help some patients (but accumulators hurt) A 2020 update to my all-time favorite chart Plus, thoughtful perspectives on diversity from AmerisourceBergen CEO Steve Collis. d/b/a Drug Channels Institute.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 24, 2021
Lucentis has been approved by the FDA since 2006 for wet AMD and is a big earner for both Roche and Novartis, who share rights to the product with Roche selling the drug in the US and Novartis selling it in Europe and other markets. Last year, Roche booked around $1.5 billion in US sales, while Novartis’ sales of the drug topped $1.9
pharmaphorum
FEBRUARY 26, 2021
During this tenure, J&J entered into the areas of vision care, mechanical wound closure and diabetes management. In 2006, J&J acquired Pfizer Consumer Healthcare for $16.6 Acquisitions post-Janssen. Between 1976 and 1989, James E. Burke was chairman and CEO of J&J. billion in cash.
PharmaShots
MARCH 29, 2023
Some companies accept the offered period and open doors to biological drugs or biosimilars. Indication: Type 2 Diabetes Mellitus Victoza is a non-insulin, anti-diabetic medicine used for the treatment of type 2 diabetes and to reduce the risk of cardiovascular events associated with the disease.
pharmaphorum
DECEMBER 2, 2020
Others rapidly followed, including Glucotrol, aimed at diabetics, and Procardia, an anti-hypertensive. One thing that highlighted this changed focus was the appointment of Kindler as CEO in 2006. The 1990s and 2000s would soon take this blockbuster-based success to new levels.
PharmaShots
APRIL 13, 2023
by the sales of Humira 2006 Johnson & Johnson recorded global sales of $53.3B in the year 2006, thereby depicting a growth rate of 5.6%. in revenue following the addition of Pfizer’s consumer health business in the year 2006. in revenue following the addition of Pfizer’s consumer health business in the year 2006.
Expert insights. Personalized for you.
98 
Let's personalize your content